Response to Jacobs: N Latex FLC serum free light-chain assays in patients with renal impairment

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 11, 2014, Pages e243-e245

  Berlanga, Oscar ^a   Carr Smith, Hugh ^a   Harding, Stephen ^a  

^a Binding Site Group Ltd   (United Kingdom)

Author keywords

chronic kidney disease (CKD); free light chains (FLC); renal failure

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; LATEX;

ASSAY; CHRONIC KIDNEY DISEASE; FREE LIGHT CHAIN TEST; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; LIGHT CHAIN; MYELOMA; N LATEX ASSAY; SEVERE RENAL IMPAIRMENT; BLOOD; BLOOD ANALYSIS; CHRONIC KIDNEY FAILURE; PROCEDURES;

BLOOD CHEMICAL ANALYSIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LATEX; RENAL INSUFFICIENCY, CHRONIC;

EID: 84908082843     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0420     Document Type: Letter

References (14)

1. Jacobs JF, Hoedemakers RM, Teunissen E, Te VH. N Latex FLC serum free light-chain assays in patients with renal impairment. Clin Chem Lab Med 2014;52:853-9
2. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274-8
3. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2
4. Lock RJ, Saleem R, Roberts EG, Wallage MJ, Pesce TJ, Rowbottom A, et al. A multicentre study comparing two methods for serum free light chain analysis. Ann Clin Biochem 2013;50:255-61
5. Mollee P, Tate J, Pretorius CJ. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med 2013;51:2303-10
6. Hoedemakers RM, Pruijt JF, Hol S, Teunissen E, Martens H, Stam P, et al. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2012;50:489-95
7. Marshall G, Tate J, Mollee P. Borderline high serum free light chain kappa/lambda ratios are seen not only in dialysis patients but also in non-dialysis-dependent renal impairment and inflammatory states. Am J Clin Pathol 2009;132:309
8. Abadie JM, van Hoeven KH, Wells JM. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis? Am J Clin Pathol 2009;131:166-71
9. Bargnoux AS, Simon N, Garrigue V, Dupuy AM, Badiou S, Mourad G, et al. Glomerular filtration rate as a determinant of free light chains in renal transplantation. Clin Biochem 2013;46:1764-6
10. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008;9:11
11. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684-90
12. Tate J, Bazeley S, Klinberg S, Pretorius CJ, Hawley C, Mollee P. Comparison of the Freelite and N Latex serum free light chain (FLC) assays in chronic kidney disease [abstract]. Clin Biochem Rev 2012;33:S41
13. te VH, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N Latex FLC-new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011;49:1323-32
14. Vermeersch P, Vercammen M, Holvoet A, Vande Broek I, Delforge M, Bossuyt X. Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders. Clin Chim Acta 2009;410:54-8.